Karuna Therapeutics, Inc. (KRTX): Price and Financial Metrics


Karuna Therapeutics, Inc. (KRTX)

Today's Latest Price: $78.80 USD

3.70 (-4.48%)

Updated Oct 28 10:15am

Add KRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

KRTX Stock Price Chart Interactive Chart >

Price chart for KRTX

KRTX Price/Volume Stats

Current price $78.80 52-week high $152.00
Prev. close $82.50 52-week low $12.48
Day low $78.63 Volume 10,741
Day high $81.91 Avg. volume 267,447
50-day MA $78.73 Dividend yield N/A
200-day MA $85.76 Market Cap 2.10B

Karuna Therapeutics, Inc. (KRTX) Company Bio


Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.


KRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

KRTX Latest Social Stream


Loading social stream, please wait...

View Full KRTX Social Stream

Latest KRTX News From Around the Web

Below are the latest news stories about Karuna Therapeutics Inc that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Karuna Therapeutics (KRTX) Investor Presentation - Slideshow

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Karuna Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced financial results for the second quarter of 2020 and provided a general business update. “We’ve made tremendous progress in advancing our clinical development programs evaluating KarXT in neuropsychiatric

Business Wire | August 5, 2020

Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced results from KAR-020, its Phase 1b trial evaluating the analgesic effects of KarXT on experimentally induced pain in healthy volunteers. Topline results of this exploratory trial were inconclusive and do

Business Wire | August 3, 2020

Karuna Therapeutics to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that senior management will participate in the following upcoming virtual investor conferences: William Blair’s Biotech Focus Conference Date: Thursday, August 6, 2020 Time: 10:00 a.m. EDT Wedbus

Business Wire | July 30, 2020

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration

BOSTON & PARAMUS, N.J.--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, and PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, today announced that the companies have entered a multi-year drug discovery and development agreement to i

Business Wire | July 28, 2020

Read More 'KRTX' Stories Here

KRTX Price Returns

1-mo 2.20%
3-mo -3.97%
6-mo -1.88%
1-year 517.07%
3-year N/A
5-year N/A
YTD 4.59%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6691 seconds.